© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 24, 2015, the consensus forecast amongst 35 polled investment analysts covering GlaxoSmithKline plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 21, 2013. The previous consensus forecast advised that GlaxoSmithKline plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 24 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,539.5, with a high estimate of 1,810 and a low estimate of 1,250. The median estimate represents a -0.13 % decrease from the last price of 1,541.5. View Full Financials
In 2014, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, which represents a 2.56% increase over last year. The 16 analysts covering the company expect dividends of 0.81 GBP for the upcoming fiscal year, an increase of 0.88%. View Full Financials
|Div growth (TTM)||+2.56 %|
On Feb 04, 2015, GlaxoSmithKline plc reported 4th quarter 2014 earnings of 0.215 per share. This result under-performed the 0.26 consensus expectations of the 9 analysts following the company but under-performed last year's 4th quarter results by 28.57 %.
The next earnings announcement is expected on Apr 29, 2015. View Full Interim Financials
|Average growth rate||-3.89 %|
GlaxoSmithKline plc reported annual 2014 earnings of 0.954 per share on Feb 04, 2015. View Full Annual Financials
|Average growth rate||-7.49 %|
GlaxoSmithKline plc had 4th quarter 2014 revenues of 6.19bn. This missed the 6.21bn consensus estimate of the 9 analysts following the company. This was 9.56% above the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||-2.14 %|
GlaxoSmithKline plc had revenues for the full year 2014 of 23.01bn. This was 13.20 % below the prior year's results. View Full Annual Financials
|Average growth rate||-4.99 %|